A Phase 1/2 interventional study of EO2401 and Nivolumab in Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma, sponsored by Enterome. Terminated at 12 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Enterome · Phase 1/2, Interventional, and Treatment
How we know · 8 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered in combination with nivolumab to generate preliminary safety and efficacy data in patients with Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
94 studies on the registry are indexed under Adrenocortical Carcinoma; 26 are open to participants now.
This study's enrollment of 70 is above the median of 35 across 71 interventional studies indexed under Adrenocortical Carcinoma.
Browse Adrenocortical Carcinoma studies →Enterome is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1:3-by-3 design of EO2401 in combination with nivolumab at standard dose. Three to 12 evaluable patients with adrenal carcinoma or progressive malignant pheochromocytoma/paraganglioma will be included depending on the safety profile of the administered treatments. Cohorts 2A (previously treated patients) and 2B (previously untreated patients): evaluation of EO2401in combination with nivolumab in 33 patients with adrenal carcinoma. Cohorts 3A (previously treated patients) and 3B (previously untreated patients) : evaluation of EO2401 combination with nivolumab in 20 patients (globally for both Cohorts 3A and 3B) with progressive malignant pheochromocytoma/ paraganglioma.
Biological: EO2401 · Biological: Nivolumab
Randomized extension of Cohort 2A (65 patients using a 4:1:1 ratio): 43 patients belonging to this extension of Cohort 2A will be treated by EO2401 and nivolumab in combination.
Biological: EO2401 · Biological: Nivolumab
11 patients belonging to this extension of Cohort 2A will be treated by EO2401 alone.
Biological: EO2401
11 patients belonging to this extension of Cohort 2A who will be treated by nivolumab alone.
Biological: Nivolumab
Multiple dose of EO2401
Multiple dose of nivolumab
Treatment-Emergent Serious Adverse Events Assessment
Incidences of treatment-emergent serious adverse events using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.
Time frame: 46 months maximum (from baseline up to study end)
Treatment-Emergent Non-Serious Adverse Events
Incidences of treatment-emergent non-serious adverse events using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.
Time frame: 46 months maximum (from baseline up to study end)
All Cause Mortalities Assessment
Incidence of death
Time frame: 46 months maximum (from baseline up to study end)
Evaluation of Progression Free Survival
Progression Free Survival according to iRECIST criteria at 6 months
Time frame: 6 months after treatment start
Evaluation of Survival
Overall survival, defined as the time interval from the date of first study treatment administration to the date of death due to any cause
Time frame: 46 months maximum (from baseline up to study end)
Percentage of Patients With Immunogenicity Against EO2401
Expansion of specific T cells comparing samples taken at baseline versus on treatment in an individual patient determining if the patient has a positive response to peptides that compose EO2401, or not. EO2401 immunogenicity is assessed by interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) (IVS and ex vivo).
Time frame: 7 weeks after treatment start
Cohort 1 safety lead-in assessed safety and tolerability of EO2401 in combination with nivolumab during 4 weeks. Evaluable patients in Cohort 1 will be assessed as part of the planned Cohorts 2A (non-randomized) and 3A, respectively. The schedule of EO2401 and nivolumab administrations are the same in Cohorts 2A (non randomized) and Cohort 3A as in Cohort 1.
| Milestone | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) |
|---|---|---|---|---|---|---|---|
| Started | 26 | 13 | 2 | 4 | 7 | 13 | 5 |
| Started and originally enrolled in cohort 1 (safety lead-in). | 2 | 0 | 0 | 0 | 0 | 1 | 0 |
| Completed | 26 | 13 | 2 | 4 | 7 | 13 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Incidences of treatment-emergent serious adverse events using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.
| Participants | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) |
|---|---|---|---|---|---|---|---|
| Treatment-Emergent Serious Adverse Events Assessment | 5 | 4 | 1 | 0 | 1 | 4 | 2 |
Incidences of treatment-emergent non-serious adverse events using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.
| Participants | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) |
|---|---|---|---|---|---|---|---|
| Treatment-Emergent Non-Serious Adverse Events | 26 | 13 | 2 | 4 | 7 | 13 | 5 |
Incidence of death
| Participants | Cohort 21 (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) |
|---|---|---|---|---|---|---|---|
| All Cause Mortalities Assessment | 21 | 5 | 1 | 2 | 6 | 9 | 0 |
Progression Free Survival according to iRECIST criteria at 6 months
| months | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) |
|---|---|---|---|---|---|---|---|
| Evaluation of Progression Free Survival | 1.9 (1.8 to 2.3) | 1.9 (1.7 to 2.5) | 1.6 (1.2 to NA) | 1.7 (1.2 to NA) | 1.9 (1.2 to 2.7) | 5.2 (1.9 to 12.2) | 19.4 (3.9 to NA) |
Overall survival, defined as the time interval from the date of first study treatment administration to the date of death due to any cause
| months | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) |
|---|---|---|---|---|---|---|---|
| Evaluation of Survival | 11.9 (2.2 to 22.9) | NA (8.6 to NA) | NA (3.0 to NA) | NA (1.6 to NA) | 24.2 (1.2 to 33.5) | 11.4 (4.6 to NA) | NA (NA to NA) |
Expansion of specific T cells comparing samples taken at baseline versus on treatment in an individual patient determining if the patient has a positive response to peptides that compose EO2401, or not. EO2401 immunogenicity is assessed by interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) (IVS and ex vivo).
| Participants | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) |
|---|---|---|---|---|---|---|---|
| Percentage of Patients With Immunogenicity Against EO2401 | 12 | 8 | 0 | 0 | 3 | 5 | 2 |
Collected over 46 months maximum (from baseline up to study end). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 2A (Non-randomized) | 21/26 (80.8%) | 5/26 (19.2%) | 26/26 (100%) |
| Randomized Extension of Cohort 2A (3 Arms): C2A-I | 5/13 (38.5%) | 4/13 (30.8%) | 13/13 (100%) |
| Randomized Extension of Cohort 2A (3 Arms): C2A-II | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| Randomized Extension of Cohort 2A (3 Arms): C2A-III | 2/4 (50%) | 0/4 (0%) | 4/4 (100%) |
| Cohort 2B (Non-randomized) | 6/7 (85.7%) | 1/7 (14.3%) | 7/7 (100%) |
| Cohort 3A (Non-randomized) | 9/13 (69.2%) | 4/13 (30.8%) | 13/13 (100%) |
| Cohort 3B (Non-randomized) | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Event | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) |
|---|---|---|---|---|---|---|---|
| SubileusGastrointestinal disorders | 0/26 | 0/13 | 1/2 | 0/4 | 0/7 | 0/13 | 0/5 |
| GastroenteritisInfections and infestations | 0/26 | 0/13 | 0/2 | 0/4 | 0/7 | 0/13 | 1/5 |
| Renal failureRenal and urinary disorders | 0/26 | 0/13 | 0/2 | 0/4 | 0/7 | 0/13 | 1/5 |
| Cardiac failureCardiac disorders | 0/26 | 0/13 | 0/2 | 0/4 | 1/7 | 0/13 | 0/5 |
| ConstipationGastrointestinal disorders | 0/26 | 0/13 | 0/2 | 0/4 | 0/7 | 1/13 | 0/5 |
| Face oedemaGeneral disorders | 0/26 | 0/13 | 0/2 | 0/4 | 0/7 | 1/13 | 0/5 |
| HyperthermiaGeneral disorders | 0/26 | 1/13 | 0/2 | 0/4 | 0/7 | 0/13 | 0/5 |
| Mucosal inflammationGeneral disorders | 0/26 | 1/13 | 0/2 | 0/4 | 0/7 | 0/13 | 0/5 |
| PyrexiaGeneral disorders | 2/26 | 0/13 | 0/2 | 0/4 | 0/7 | 0/13 | 0/5 |
| HepatotoxicityHepatobiliary disorders | 0/26 | 1/13 | 0/2 | 0/4 | 0/7 | 0/13 | 0/5 |
| Event | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) |
|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 9/26 | 6/13 | 2/2 | 0/4 | 3/7 | 6/13 | 2/5 |
| AstheniaGeneral disorders | 4/26 | 9/13 | 0/2 | 1/4 | 2/7 | 2/13 | 2/5 |
| DiarrhoeaGastrointestinal disorders | 9/26 | 4/13 | 0/2 | 0/4 | 3/7 | 2/13 | 3/5 |
| Injection site painGeneral disorders | 5/26 | 2/13 | 0/2 | 0/4 | 0/7 | 4/13 | 3/5 |
| Abdominal herniaGastrointestinal disorders | 0/26 | 0/13 | 1/2 | 0/4 | 0/7 | 0/13 | 0/5 |
| Abdominal painGastrointestinal disorders | 5/26 | 3/13 | 1/2 | 1/4 | 0/7 | 1/13 | 1/5 |
| Abdominal pain upperGastrointestinal disorders | 1/26 | 2/13 | 1/2 | 0/4 | 0/7 | 1/13 | 0/5 |
| NauseaGastrointestinal disorders | 5/26 | 5/13 | 1/2 | 0/4 | 0/7 | 0/13 | 2/5 |
| FatigueGeneral disorders | 6/26 | 1/13 | 1/2 | 1/4 | 3/7 | 3/13 | 0/5 |
| Alanine aminotransferase increasedInvestigations | 4/26 | 3/13 | 1/2 | 1/4 | 2/7 | 1/13 | 0/5 |
| Age, Continuous(years) | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) | Total |
|---|---|---|---|---|---|---|---|---|
| Median | 46 (31 to 61) | 54 (35 to 73) | 49.5 (38 to 61) | 52.5 (19 to 65) | 47 (43 to 72) | 55 (48 to 61) | 63 (36 to 64) | 51 (19 to 85) |
| Sex: Female, Male(Participants) | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 18 | 10 | 0 | 3 | 7 | 4 | 4 | 46 |
| Male | 8 | 3 | 2 | 1 | 0 | 9 | 1 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 26 | 13 | 2 | 4 | 7 | 13 | 4 | 69 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 26 | 13 | 2 | 4 | 7 | 13 | 5 | 70 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 2A (Non-randomized) | Randomized Extension of Cohort 2A (3 Arms): C2A-I | Randomized Extension of Cohort 2A (3 Arms): C2A-II | Randomized Extension of Cohort 2A (3 Arms): C2A-III | Cohort 2B (Non-randomized) | Cohort 3A (Non-randomized) | Cohort 3B (Non-randomized) | Total |
|---|---|---|---|---|---|---|---|---|
| Sweden | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Netherlands | 5 | 2 | 1 | 1 | 2 | 2 | 0 | 13 |
| United States | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 3 |
| Denmark | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Italy | 8 | 5 | 1 | 1 | 2 | 5 | 1 | 23 |
| France | 7 | 6 | 0 | 1 | 2 | 2 | 3 | 21 |
| Germany | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 4 |
| Spain | 3 | 0 | 0 | 0 | 0 | 1 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Safety and efficacy data
Supporting information: Study protocol, Statistical analysis plan
Time frame: Oct 2025
Access criteria: Primary and key secondary outcomes
Ran from Jul 2020 to primary completion in Oct 2024, 50 months.
Results were first posted in Jan 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Enterome